相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
Erik Kupperman et al.
CANCER RESEARCH (2010)
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib
Roberto Piva et al.
BLOOD (2008)
Image-based screening for the identification of novel proteasome inhibitors
Linda Rickardson et al.
JOURNAL OF BIOMOLECULAR SCREENING (2007)
Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
Mark J. Williamson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
S Lonial et al.
BLOOD (2005)
Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies
H Ludwig et al.
CANCER (2005)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
The development of proteasome inhibitors as anticancer drugs
J Adams
CANCER CELL (2004)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Proteasome inhibitor PS-341 induces a apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells
A Fribley et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells
AH Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Imaging 26S proteasome activity and inhibition in living mice
GD Luker et al.
NATURE MEDICINE (2003)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp MK993-dF2 -: I.: Taxonomy, isolation, physico-chemical properties and biological activities
S Momose et al.
JOURNAL OF ANTIBIOTICS (2001)
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells
NP Dantuma et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
